Jul. 1 at 2:08 AM
$CRDL he Path to
$10,
$20, or
$30FOR micro-cap biotech firms, stock prices typically move in explosive, step-like gaps triggered by clinical milestones rather than steady, linear growth.
1- Reaching
$10 (Highly Feasible on Success):
If the Phase III MAVERIC trial yields strong, clean data and the company submits a successful New Drug Application (NDA) to the FDA, hitting the
$8.00 to
$10.00 range matches analyst expectations.
2- Reaching
$20 (Requires Commercial Proof): To double from there and hit
$20, CardiolRx™ would likely need to transition successfully into the marketplace. This requires strong initial insurance coverage, robust multi-million dollar commercial sales, or expanding the drug's use to treat other conditions, such as acute myocarditis.
3 in reply
